Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D, Petrak J. Hrdinova T, et al. Among authors: polivkova v. Int J Oncol. 2021 Feb;58(2):238-250. doi: 10.3892/ijo.2020.5163. Epub 2020 Dec 23. Int J Oncol. 2021. PMID: 33491750
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.
Razga F, Racil Z, Machova Polakova K, Buresova L, Klamova H, Zackova D, Dvorakova D, Polivkova V, Cetkovsky P, Mayer J. Razga F, et al. Among authors: polivkova v. Int J Hematol. 2011 Sep;94(3):303-306. doi: 10.1007/s12185-011-0924-6. Epub 2011 Sep 8. Int J Hematol. 2011. PMID: 21901397 No abstract available.
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Polivkova V, et al. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016. PLoS One. 2016. PMID: 27214026 Free PMC article.
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, Klamova H, Pecherkova P, Belohlavkova P, Vrbacky F, Machova Polakova K. Jaruskova M, et al. Among authors: polivkova v. J Exp Clin Cancer Res. 2017 Apr 18;36(1):55. doi: 10.1186/s13046-017-0523-3. J Exp Clin Cancer Res. 2017. PMID: 28420426 Free PMC article.
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
Machova Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, Glauche I, Koblihova J, Pecherkova P, Klamova H, Stastna Markova M, Srbova D, Benesova A, Polivkova V, Jurcek T, Zackova D, Mayer J, Ernst T, Mahon FX, Saussele S, Roeder I, Cross NCP, Hochhaus A. Machova Polakova K, et al. Among authors: polivkova v. Leukemia. 2020 Aug;34(8):2113-2124. doi: 10.1038/s41375-020-0882-1. Epub 2020 May 29. Leukemia. 2020. PMID: 32472084
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.
Curik N, Polivkova V, Burda P, Koblihova J, Laznicka A, Kalina T, Kanderova V, Brezinova J, Ransdorfova S, Karasova D, Rejlova K, Bakardjieva M, Kuzilkova D, Kundrat D, Linhartova J, Klamova H, Salek C, Klener P, Hrusak O, Machova Polakova K. Curik N, et al. Among authors: polivkova v. Front Oncol. 2021 Sep 20;11:744373. doi: 10.3389/fonc.2021.744373. eCollection 2021. Front Oncol. 2021. PMID: 34616685 Free PMC article.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M. Machova Polakova K, et al. Among authors: polivkova v. Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21. Leukemia. 2024. PMID: 38129513 Free PMC article.
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Benesova A, et al. Among authors: polivkova v. Am J Hematol. 2024 Apr;99(4):759-762. doi: 10.1002/ajh.27232. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38314531 No abstract available.
20 results